JPMorgan analyst Chris Schott raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $14 from $12 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but increased price targets on a move to December 2026 from December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals receives FDA approval of sodium oxybate oral solution
- Amneal gets FDA approval for risperidone extended-release injectable suspension
- Amneal Pharma Reports Strong Q2 2025 Results
- Amneal Pharma’s Optimistic Q2 Earnings Call Highlights
- Knight Therapeutics announces CREXONT regulatory submission in Mexico